Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Addition of Umeclidinium to FF/VI in COPD
NCT01957163Phase 3Completed
- Sponsor
- GSK
- Start
- Oct 2013
- Primary completion
- Apr 2014
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 3, randomised, double-blind trial of umeclidinium in chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by GSK. Primary endpoint: Change From Baseline in Trough Forced Expiratory Volume in One Second at Day 85. Started Oct 2013; status: completed.
02
Drugs
umeclidinium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT01957163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01957163.